Smoking cessation may deteriorate glycemic control in diabetic patients
the ONA take:
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years, according to a recent study published in The Lancet Diabetes & Endocrinology.
Researchers led by Deborah Lycett, PhD, of Convetry University studied primary care records of 10,692 adult smokers with type 2 diabetes mellitus over six years to see if there was any association between diabetes control and smoking cessation.
They found that in 3,131 people (29 percent) who had quit for at least one year, HbA1c increased by 2.3 mmol/mol before gradually decreasing as abstinence continued.
During the same amount of time, 5,831 (55 percent) of patients who continually smoked experienced a more gradual increase in HbA1c. Those who quit saw comparable HbA1c levels with continual smokers after three years of quitting.
“Knowing that deterioration in blood glucose control occurs around the time of stopping smoking helps to prepare those with diabetes and their clinicians to be proactive in tightening their glycemic control during this time,” Dr. Lycett concluded.
Patients with type 2 diabetes mellitus who quit smoking see a temporary deterioration in glycemic control that may last up to three years.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|